FDA Plans Looser Rules on Approving Alzheimer's Drugs

The Food and Drug Administration plans to loosen the rules for approving new treatments for Alzheimer’s disease.

Drugs in clinical trial would qualify for approval if people at very early stages of the disease subtly improved their performance on memory or reasoning tests, even before they developed any obvious impairments. Companies would not have to show that the drugs improved daily, real-world functioning.

Read the full story: http://nyti.ms/ZKruru

Source: The New York Times